Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy [Phase 2]
Phase 2 trial evaluating surufatinib plus sintilimab in metastatic neuroendocrine tumors and pancreatic carcinoma after failure of standard …
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases [Phase 2, Phase 3]
A clinical trial update for intra-arterial Lutetium-177-dotatate in neuroendocrine tumor patients with liver metastases (Phase 2 and Phase 3…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs [Phase 2]
Phase 2 clinical trial update evaluating an amino acid–based medical food for diarrhea in neuroendocrine tumors, including carcinoid syndrom…
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors [Phase 2, Phase 3]
Phase 2/3 trial investigating Al18F-NOTA-octreotide PET imaging for neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) [Phase 2]
Phase 2 trial evaluation of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid tumors has compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors [Phase 1, Phase 2]
Clinical trial updates for Gallium-68 labeled LM3 PET/CT in neuroendocrine tumors across Phase 1 and Phase 2, completed.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm [Phase 2]
Phase 2 trial evaluating chidamide plus sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm; status not yet de…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT [Phase 2]
Phase 2 trial comparing Ga-DOTATOC PET sensitivity to Octreoscan SPECT+CT in medulloblastoma and related neuroendocrine tumors; results post…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET [Phase 2]
A Phase 2 trial is investigating the safety and activity of combining cabozantinib with lanreotide in metastatic well-differentiated neuroen…
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors [Phase 2]
Phase 2 trial update on combining interferon-alpha with metronomic cyclophosphamide in neuroendocrine tumors has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2021-03-09Clinical Trial Update: A Study of Pembrolizumab in Patients With Neuroendocrine Tumors [Phase 2]
Phase 2 trial of pembrolizumab in patients with neuroendocrine tumors has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: Impact of Peptides and Chelators on Somatostatin Receptor Antagonists [Phase 2]
Phase 2 clinical trial update evaluating the impact of peptides and chelators on somatostatin receptor antagonists for neuroendocrine tumors…
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study [Phase 2]
A Phase II investigator-initiated trial evaluating safety and tolerability of everolimus as second-line therapy in poorly differentiated neu…
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors [Phase 2]
Phase 2 trial investigating RAD001 ( everolimus ) and erlotinib in patients with neuroendocrine tumors; study terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Octreotide LAR in the Induction of Immunologic Response in NENs Patients [Phase 2]
Phase 2 trial update evaluating octreotide LAR for inducing immunologic response in neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: DEBOXA for Inoperable NET Liver Metastases [Phase 1, Phase 2]
Clinical trial update for DEBOXA in inoperable neuroendocrine tumor liver metastases, spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study [Phase 2]
Phase 2 clinical trial update evaluating Holmium-166 radioembolization in neuroendocrine tumors after Lutetium-177-dotatate.
-
CLINICAL_TRIALS trial_result · 2020-06-01Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors [Phase 2]
Pazopanib hydrochloride is being studied in a Phase 2 trial for progressive carcinoid tumors (neuroendocrine tumors); the study status is ac…
-
CLINICAL_TRIALS trial_result · 2020-04-01Clinical Trial Update: Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression [Phase 2]
Phase 2 clinical trial evaluating peptide receptor radionuclide therapy for advanced, non-resectable or symptomatic tumors with SSTR overexp…
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors [Phase 2, Phase 3]
A phase 2/3 trial evaluating combination chemotherapy with bevacizumab in advanced neuroendocrine tumors has been terminated; results were p…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with …
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors [Phase 2]
Phase 2 multicenter trial evaluating 177Lu-DOTA-TATE with kidney dosimetry in patients with disseminated neuroendocrine tumors, completed.
-
CLINICAL_TRIALS trial_result · 2019-03-04Clinical Trial Update: Pazopanib as Single Agent in Advanced NETs [Phase 2]
Phase 2 trial of pazopanib as a single agent in advanced/metastatic neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe [Phase 2]
Phase 2 RAMSETE trial evaluating RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumors; results were posted in January…
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors [Phase 1]
A Phase 1 trial evaluating LY2584702 combined with erlotinib or everolimus in patients with solid tumors was terminated, and results have be…